← Back to Home

Full Phase 3 Data on a Personalized Cancer Vaccine: Tumor Samples and Treatment Waits Pose Practical Challenges

The melanoma trial showed a vaccine manufacturing success rate of over 99% after screening, but about 17% of screened patients were excluded because of insufficient tumor samples. Newly disclosed discontinuation and survival data also make considerations beyond efficacy more concrete.

By SURL BioNews

The challenges of making a cancer vaccine tailored to each patient begin with obtaining a tumor sample. Full data from the Phase 3 melanoma trial of the personalized mRNA therapy intismeran autogene confirmed its benefit in reducing recurrence after surgery while also revealing barriers to treatment: some patients could not participate because of insufficient samples at screening, and the median time to the first dose among vaccine recipients was 64 days.

According to CancerNetwork’s summary of the presentation at the European Society for Medical Oncology (ESMO) annual meeting, INTerpath-001 screened 1,749 people, of whom 302, or about 17.3%, were excluded because of insufficient tumor samples. Moderna stated that the vaccine manufacturing success rate exceeded 99% for patients randomly assigned to the combination treatment group. These two figures describe different stages: a high manufacturing success rate does not mean that everyone who comes for evaluation can receive the therapy; nor can the 64 days be directly interpreted as manufacturing time alone.

Safety data also added a perspective beyond the efficacy figures. Rates of grade 3 to 5 treatment-related adverse events were similar in the vaccine plus pembrolizumab group and the control group, at 14.2% and 13.4%, respectively; however, 14.0% and 8.7%, respectively, discontinued either study drug because of treatment-related adverse events. Similar severity grades may still be accompanied by different burdens on treatment continuation.

Whether the therapy can extend life remains uncertain. According to CancerNetwork’s summary, the overall survival analysis yielded a hazard ratio of 0.77, with a 95% confidence interval of 0.45 to 1.31 and a P value of 0.33, which did not meet the prespecified significance threshold. The data remain immature and cannot support a claim of a survival benefit, nor can they establish that the possibility of extending life has been ruled out.

Background

The trial enrolled 1,137 patients with stage IIB to IV melanoma whose tumors had been completely resected, comparing the vaccine plus pembrolizumab with placebo plus pembrolizumab. Moderna and The American Journal of Managed Care (AJMC) both reported that, after a median follow-up of 24.6 months, the combination group had a 42% reduction in the relative risk of recurrence or death; the two-year recurrence-free survival rate was 82.2%, compared with 70.0% in the control group, a difference of 12.2 percentage points. This result measures a composite endpoint of recurrence or death and cannot be equated with a 42% reduction in the risk of death.

Intismeran autogene, also known as V940 or mRNA-4157, selects up to 34 neoantigens based on mutations in a patient’s tumor and encodes recognition cues into mRNA, with the aim of guiding the immune system to recognize cancer cells; pembrolizumab blocks PD-1 inhibitory signaling to help T cells function. This is a treatment strategy designed for patients who already have cancer, rather than a vaccine for preventing cancer in the general population.

The full data broaden the evaluation of this therapy from “can it reduce recurrence?” to “which patients can successfully receive and complete treatment?” The therapy remains investigational; obtaining samples, the time required before the first dose, and the higher rate of treatment-related discontinuation will all be important considerations in understanding its practical applicability. Whether overall survival can improve still requires further follow-up.

References

  1. Moderna
  2. The American Journal of Managed Care
  3. CancerNetwork